4Cell Therapies

4Cell Therapies is a Brazilian biotechnology company focused on the development and commercialization of advanced cell therapies, specifically Chimeric Antigen Receptor (CAR) T-cell treatments. The company aims to provide cost-effective immunotherapy solutions for cancer patients in Brazil and Latin America, addressing hematological malignancies like B-cell lymphoma and leukemia. 4Cell Therapies utilizes a proprietary platform for genetic engineering of T-cells and has established strong ties with academic centers of excellence. Their lead candidate targets the CD19 antigen and has progressed into clinical evaluation. By localizing production and development, the company seeks to overcome the high costs and logistical challenges associated with imported cell therapies. The firm is a prominent player in the emerging South American biopharmaceutical ecosystem.